Summit Therapeutics Inc (SMMT)

Summit Therapeutics experienced several stock events in the past six months. In October 2025, the company reported a wider-than-expected loss per share for Q3 2025 and announced plans to submit a BLA for ivonescimab despite FDA guidance. In January 2026, Citizens reiterated a "Market Outperform" rating. February 2026 saw the company report its Q4 2025 earnings, again with a wider-than-expected loss per share. In March 2026, Jefferies downgraded Summit Therapeutics to "Hold" and cut its price target, while H.C. Wainwright also lowered its price target, and Citizens reaffirmed its "Market Outperform" rating. The company also announced that multiple ivonescimab data sets would be featured at ELCC 2026. As of early April 2026, the stock price has experienced volatility.

As a clinical-stage biopharmaceutical company, Summit Therapeutics does not currently experience direct demand seasonality for its products or services.

Summit Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel therapeutics for unmet medical needs, particularly in oncology and infectious diseases. The company's core strategy involves advancing differentiated drug candidates through late-stage clinical development, with its primary value driver being its oncology pipeline, led by ivonescimab. While the company previously focused on antibiotics, it has shifted towards oncology through asset acquisitions and licensing agreements.

Summit Therapeutics is headquartered in Miami, Florida, with additional operations in Palo Alto, California; Princeton, New Jersey; Oxford, United Kingdom; and Dublin, Ireland. The company has international influence through a collaboration with Akeso, Inc. in China and maintains strategic exposure to North America, Europe, Japan, Latin America, the Middle East, and Africa through licensing rights.

Summit Therapeutics has achieved the "Great Place to Work® Certification™." The company's external reputation has been influenced by the progress and challenges of ivonescimab, including the failure to achieve a statistically significant overall survival benefit in a Phase 3 clinical study and the decision to proceed with a BLA despite FDA guidance, leading to analyst downgrades. Concerns about the company's reliance on a single asset and legal and regulatory risks also affect its reputation.

Summit Therapeutics Inc. has a significant number of institutional owners and shareholders. Major institutional shareholders include Baker Bros. Advisors Lp, Fmr Llc, Vanguard Group Inc, Price T Rowe Associates Inc /md/, BlackRock, Inc., State Street Corp, Geode Capital Management, Llc, Citadel Advisors Llc, and Susquehanna International Group, Llp. Key individual insider owners include Mahkam Zanganeh, Robert W. Duggan, Yu Xia, and Maky Zanganeh.